$POAI Closes on $7.4M Registered Direct Offering, Announces Breakthrough Discoveries

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it had closed on its previously announced registered direct offering. The offering, comprised of 4,222,288 shares of POAI common stock sold at $1.75 per share, totaled $7.4 million in gross proceeds for the company, before expenses were deducted. The shares were priced at-the-market under Nasdaq rules. The announcement also noted that the company issued a concurrent private placement to the same investors; that placement comprised of unregistered warrants up 2,111,144 shares of common stock, priced at $2 per share. In a second announcement, Predictive Oncology noted that, using TumorGenesis technology, two top researchers have identified breakthrough discoveries in understanding how ovarian cancer cells migrate outside the abdominal cavity, or omentum. TumorGenesis is a wholly owned subsidiary of Predictive Oncology. Conducted by a top-tier laboratory in Massachusetts, the research relied on TumorGenesis media to capture, culture and identify how cells break through the protective lining in the abdomen. The study findings could result in the development of drugs that target against that receptor site of the abdominal lining to effectively bloc the metastasis of re-occurring ovarian cancer. “Both targets of the research aided by TumorGenesis’s technology, blocking the omentum penetration and blocking the enzyme that accelerates a response to PARP treatment, once developed and approved, represent several billion dollars in future revenues for biotech or pharma companies,” said Predictive Oncology CEO Dr. Carl Schwartz in the press release. “Three currently available PARP inhibitors, each becoming resistant to ovarian cancer over time, generate $2.8 billion in revenue for such companies. That is why TumorGenesis is expanding its product lines, offering services, and helping pharma, biotech, and researchers around the world to unravel cancer’s mysteries.”

To view the full press releases, visit https://ibn.fm/Tjdjf and https://ibn.fm/VyyW1

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.  Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA (“DNA/RNA”) and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$PLTXF Prices Offering and Files Amended and Restated Preliminary Short Form Prospectus

VANCOUVER, BC , Feb. 17, 2021 – PlantX Life Inc. (the ” Company ” or ” PlantX “) (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF) is pleased to announce that it has priced its previously announced offering (the ” Offering “) in its February 16, 2021 news release and has today filed an amended and restated short form preliminary short form prospectus in connection with the Offering. The Offering will be at a price of $1.25 per unit of the Company (a ” Unit “) for the issuance of a minimum of 8,000,000 Units to raise minimum total gross proceeds of $10,000,000 .  The Offering, which will be conducted on a “best efforts” agency basis, is being led by Mackie Research Capital Corporation (the ” Agent “) as lead agent and sole bookrunner.

Each Unit will consist of one (1) common share of the Company (an ” Unit Share “, each such common share in the authorized capital structure of the Company, a ” Common Share “) and one (1) Common Share purchase warrant (a ” Warrant “). Each Warrant will be exercisable at a price of $1.45 and will entitle the holder to purchase one additional Common Share (a ” Warrant Share “) for a period of two (2) years from the closing of the Offering (the ” Closing “), provided that , if, at any time, the daily volume weighted average trading price (or closing price on trading days when there are no trades) of the Common Shares on the Canadian Securities Exchange (the ” CSE “) or, if the Common Shares are not listed on the CSE, then on such other recognized Canadian stock exchange on which the Common Shares are then listed, equals or exceeds $2.50 per Common Share over any ten (10) consecutive trading days, the Company shall be entitled, at its option, within ten (10) business days following such ten-day period, to accelerate the exercise period of the Warrants through the issuance of a press release (the ” Acceleration Notice “) specifying the new expiry date and, in such case, the Warrants will expire on the 30th day following the issuance of the Acceleration Notice. From and after the new expiry date specified in such Acceleration Notice, no Warrants may be issued or exercised, and all unexercised Warrants shall be void and of no effect following the new expiry date.

The net proceeds raised under the Offering will be used to fund expansion, to continue to develop a user app, to evaluate and pursue potential strategic acquisitions, and for working capital and general corporate purposes.

The closing of the Offering is currently expected to be on or about March 11, 2021 or such other date as agreed upon between the Company and the Agent, and is subject to certain conditions including, but not limited to, the execution of an agency agreement and the receipt of all necessary regulatory approvals including the approval of the CSE.

The Units are to be sold on a “best efforts” basis through the Agent in the provinces of British Columbia , Alberta and Ontario , and such other jurisdictions as the Agent and the Company may agree other than Quebec , and in the United States pursuant to available exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the ” U.S. Securities Act “) and all applicable U.S. state securities laws.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities in the United States or to, or for the account or benefit of, U.S. persons. The securities described herein have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. “United States” and “U.S. person” are as defined in Regulation S under the U.S. Securities Act.

About PlantX Life Inc.

As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the Company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the Company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand – but the business is not limited to an e-commerce platform. The Company uses its digital platform to build a community of likeminded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The Company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life.

On behalf of the board of directors of PlantX

Julia Frank
Chief Executive Officer

The Company website is http://investor.PlantX.com/ .

Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may,” “will,” “expect,” “likely,” “should,” “would,” “plan,” “anticipate,” “intend,” “potential,” “proposed,” “estimate,” “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. The forward-looking information contained herein includes, without limitation, the business and strategic plans of the Company, expectations and assumptions regarding the terms, timing and potential completion of the Offering; satisfaction of regulatory requirements in various jurisdictions and the use of proceeds from the Offering.

By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate; that assumptions may not be correct; and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release including, without limitation: the Company’s ability to comply with all applicable governmental regulations, including all applicable food safety laws and regulations; impacts to the business and operations of the Company due to the COVID-19 epidemic; a limited operating history; the ability of the Company to access capital to meet future financing needs; the Company’s reliance on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.

Additional risk factors can also be found in the Company’s continuous disclosure documents, which have been filed on SEDAR and can be accessed at www.sedar.com . Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

$NETE President Biden’s EV Plan Faces Implementation Challenges at State Level

$MWK Diversifies its E-Commerce Portfolio Through Strategic Acquisition

$CBDHF CBD Clinical Trial at Mount Sinai, “Buzz on the Street” Show

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “HempFusion CBD to be the Exclusive Supplier for Clinical Trial at Mount Sinai Medical Hospital, New York”

HempFusion Wellness Inc. (OTCQX: CBDHF) (TSX: CBD.U) (FWB:8OO) a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that Mount Sinai Medical Hospital, New York City, has selected HempFusion CBD to be used as the exclusive brand and the sole supplier in a six-month clinical trial.

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retailers across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 46 SKUs including, tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com .

For more information, please visit: HempFusion Wellness Inc.

For more corporate news on HempFusion Wellness Inc., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

$CBDHF to Supply HempFusion CBD for Potentially Groundbreaking Research at Mount Sinai Medical Hospital

HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, has announced that Mount Sinai Medical Hospital, New York City, has selected HempFusion CBD as the exclusive brand and the sole supplier in a six-month clinical trial. Dr. David Harnick, a board-certified cardiologist and electrophysiologist and assistant professor in medicine and cardiology at Mount Sinai, is conducting the trial comprised of two studies that is one of the first of its kind in the area of CBD’s effect on targeted cardiology markers. “Studying the potential effects that CBD may have on cardiology markers may potentially unlock some of the scientific mysteries that exist today,” said Dr. Harnick. “We know that there is evidence that CBD may have beneficial effects on the body, but the exact scope of those effects remains to be determined. There have been no published randomized prospective controlled trials evaluating the effects of CBD on these cardiac markers, so this research may prove to be groundbreaking.”

To view the full press release, visit: https://cnw.fm/wrogo

About HempFusion Wellness Inc.

HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA drug listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the U.S. Hemp Roundtable, and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in-store or by visiting HempFusion online at www.Hempfusion.com or www.Probulin.com.

NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at http://cnw.fm/HempFusion

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

$CLXPF Rise In Consumer Acceptance of Psychedelic Drug Therapies Is Quickly Increasing

Palm Beach, FL – February 17, 2021 – Psychedelics are making their way out of the counterculture and back into the mainstream, with research and media interest in the mind-altering substances growing substantially. Some have even called psychedelics “psychiatry’s brave new world.” The revitalization of psychedelics has occurred alongside a shift away from the research and development of traditional psychiatric medications by leading pharmaceutical companies. A report from Data Bridge Market Research reported that the global psychedelic drugs market is rising gradually with a healthy CAGR in the forecast period of 2019-2026. Growing prevalence of depression worldwide and increase in special designation from the regulatory authorities to the company to expedite the development process are the key factors for market growth.  It said that: “Psychedelic drugs market is growing due to increase in prevalence of depression worldwide, increase special designation from the regulatory authority; the effects of these factors are: Increase in prevalence of depression worldwide : Psychedelic drugs are used for the treatment of different variants of depression and other clinical indications, although the major focus is on the treatment of depression and other different types of mental disorders. This is due to their capability of invoking consciousness changes by altering the visual and auditory functioning of the consumers.”  Active companies in the markets this week include: Mind Cure Health Inc. (OTCQB: MCURF) (CSE: MCUR), MindMed (OTCQB: MMEDF) (NEO: MMED), Numinus Wellness Inc (OTCPK: LKYSF) (TSX-V: NUMI), Cybin Inc. (OTCPK: CLXPF) (NEO: CYBN), Field Trip Health Ltd (OTCPK: FTRPF) (CSE: FTRP).

Data Bridge Market Research continued : “Therefore, the growing volume of depression in patients is directly affecting the market’s potential for growth; and Increase special designation from the regulatory authority: Another important factor behind the market’s high growth potential is the different regional authorities providing specialized designation to these drug categories helping streamline the approval process by providing the specific requirements required from the drug for its approval in a timelier manner.  With the focus of authorities to work alongside specialized research organizations and pharmaceutical manufacturers to reduce the time required for the development and commercialization of psychedelic drugs for the treatment of different indications. These partnerships between different authorities and market players are resulting in quicker drug developments, product approvals and subsequent commercialization helping solve a clinically unmet need of different patients.”

Mind Cure Health Inc. (CSE: MCUR.CNQ) (OTCQB: MCURF) BREAKING NEWS: Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics – Celebrated neurologist, psychiatrist and plant-medicine expert Dr. Dan Engle brings years of understanding of psychedelic medicine into research with Mind Cure – Mind Cure Health Inc is pleased to announce the engagement of Dr. Dan Engle as Mind Cure’s Primary Investigator Consultant. Dr. Engle is Board Certified in Psychiatry and Neurology, with a clinical practice that combines functional medicine, integrative psychiatry, neuro-cognitive restoration. He is celebrated for contribution to understanding of traumatic brain injury and concussion recovery with his book The Concussion Repair Manual . Dr. Engle is transitioning from his previous role as an advisor to Mind Cure.

Mind Cure has identified traumatic brain injury (“TBI”) as a priority indication which shares important biological pathways associated to pain. Mind Cure will investigate the therapeutic potential of psychedelic compounds for TBI and related conditions. Dr. Engle will facilitate the translation of Mind Cure’s traumatic brain injury research from pre-clinical to clinical.

“Mind Cure is fortunate that Dr. Engle has chosen to bring his expertise and clinical experience with trauma and head injury to lead Mind Cure’s research efforts,” said President and CEO Kelsey Ramsden. “Dr. Engle is a trusted resource whose guidance will be pivotal in leading this transformative research program. TBI issues not only affect individuals but also can have lasting effects on families and communities”.

Traumatic brain injuries are a major cause of death and disability in North America and are increasing in number. From 2006 to 2014, the number of TBI-related emergency department visits, hospitalizations, and deaths increased by 53%. An average 32,000 people in the United States have died each day from injuries that include a traumatic brain injury. Those who survive can face effects that last a few days or the rest of their lives, and can include issues related to emotional functioning (e.g., personality changes, depression) along with impairments related to thinking or memory, movement and sensations, such as vision or hearing. To read this and more news for Mind Cure Health, please visit https://www.financialnewsmedia.com/news-mcur/

Other recent developments in the markets include:

MindMed (NEO: MMED) (OTCQB: MMEDF), a leading psychedelic medicine biotech company recently announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties.  As part of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together. The first initial compounds have already been synthesized by MindShift Compounds AG and related patent applications were filed by MindMed. MindMed plans to begin first-in-human Phase 1 clinical trials as early as Q1 2022 through its existing clinical trial platform for psychedelic and empathogenic compounds in Switzerland.

The partnership on these initial targets will expand MindMed’s current, well-established clinical pipeline with additional backup and expansion compounds with similar and potentially improved therapeutic properties. The related synthesis intellectual property and pharmaceutical technology will be owned outright by MindMed, and MindShift Compounds AG will provide all intellectual property related to the new psychedelic compounds exclusively to MindMed.

Numinus Inc (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), has recently closed its acquisition of Mindspace Psychology Services Inc , a leader and pioneer in psychedelic programming. The purchase agreement was previously announced.

Founded by Dr. Joe Flanders in 2011, Mindspace will continue under Dr. Flanders’ leadership. The acquisition expands Numinus’ presence into Quebec, building on its Vancouver office with two established locations and extensive virtual services as well as insights garnered from a decade of successful clinic management.

Cybin Inc. (OTCPK: CLXPF) (NEO: CYBN) (CYBN.AQN), a biotechnology company focused on progressing psychedelic therapeutics, recently announced that Doug Drysdale, Chief Executive Officer, will conduct a conference call and webcast to review its financial results and provide a business update on Wednesday, February 17, 2021 @ 10:AM ET.

A replay of the conference call will be available for two weeks after the call’s completion by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (International). The conference ID for the replay is 13716476. The archived webcast will be available for 30 days on: www.cybin.com/investor-relations .

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Field Trip Health Ltd. (CSE: FTRP) (OTCQX: FTRPF), a leader in the development and delivery of psychedelic therapies, recently announced the official opening of the Field Trip Natural Products Limited Research and Development Laboratory for Psychedelic Fungi in Mona, Jamaica. The research facility, which is opening as part of Field Trip’s previously announced strategic partnership with the University of West Indies, is the world’s first legal research and cultivation facility dedicated exclusively to psilocybin-producing mushrooms and other plant-based psychedelics.

“Clinical studies on psilocybin and other plant-based psychedelic compounds have shown that they have great potential to produce profoundly positive changes in individuals, particularly those struggling from serious mental health conditions like anorexia, depression and PTSD,” said Dr. Nathan Bryson, Field Trip’s Chief Science Officer. “With the opening of this facility, Field Trip and UWI will be leaders in the understanding of psilocybin-producing fungi and how they can be best utilized in a treatment setting.”

The work at the new facility will leverage the research and development efforts that have been conducted by Field Trip at a temporary facility at UWI since January 2020, and will be broad-ranging, from genetics, breeding and cultivation work on many of the 180+ plus recorded species of psilocybin-producing mushrooms, to developing analytical methods for quality control, identification of novel molecules, as well as extractions and formulations for drug development purposes. Research at the Facility will be led by Rupika Delgoda, Professor of Biochemical Pharmacology & Pharmacognosy and Director of the Natural Products Institute at UWI, who holds a D.Phil. from Oxford University (UK) in Pharmacology.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press releases issued by Mind Cure Health Inc. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

$MOTNF Provides Update on PowerTap 3G Unit

Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF), an investment company, has announced additional information regarding PowerTap’s third-generation unit, noting that the unit has increased efficiency and reduced operating costs. The technology and unit are being developed by technology from PowerTap Hydrogen Fueling Corp., an investee company of Clean Power. According to the announcement, the system performance of PowerTap’s third-generation onsite hydrogen production module unit is controlled by advanced operating software with data analytics. Data that is collected through the software is sent through the cloud. Subsequently a data analytics application evaluates the information then deploys advance algorithms to determine critical point indicators to monitor performance characteristics; those indicators include system run, fuel dispensing rate and storage efficiency. As a result of this advanced technology, operating costs should be reduced and the life of the system is expected to be extended. “PowerTap Gen 3 continues to innovate through advancements in the design and operation of modular onsite hydrogen production fueling stations of the future maximizing our first mover advantage, said PowerTap chief operating office Kelley Owen in the press release.

To view the full press release, visit https://ibn.fm/3QxsB

About Clean Power Capital Corp.

Clean Power is an investment company that specializes in investing into private and public companies opportunistically that may be engaged in a variety of industries, with a current focus in the health and renewable energy industries. In particular, the investment mandate is focused on high-return investment opportunities, the ability to achieve a reasonable rate of capital appreciation and to seek liquidity in its investments. For more information about the company, please visit www.CleanPower.Capital.

NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at http://ibn.fm/MOTNF

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

$CNPOF Announces Shareholder Approval of Canopy Growth Plan of Arrangement

Canopy Rivers (TSX: RIV) (OTC: CNPOF) shareholders have voted to approve the company’s previously announced plan of arrangement regarding Canopy Growth Corporation. Shareholder voting resulted in 99.87% of votes cast by Rivers’ shareholders cast in favor of the arrangement; that number included an estimated 99.85% of votes cast by Rivers’ shareholders other than Canopy Growth. According to the previously announced arrangement, approval was required from at least two-thirds of the votes cast by the holders of subordinated voting shares as well as two-thirds of votes cast by Canopy Growth and a simple majority of votes cast by holders of SVS (“SVS”). The announcement also noted that Les Serres Stéphane Bertrand Inc. had exercised its right of first refusal to purchase from Rivers a proportionate interest of the common shares in Les Serres Vert Cannabis Inc. Based on that, Canopy Rivers, through RIV Capital Corporation, its wholly owned subsidiary, has entered into a definitive purchase agreement with Serres Bertrand. “We are thrilled by both the high voting turnout and the tremendous support we received for the Arrangement,” said Canopy Rivers president and CEO Narbe Alexandrian in the press release. “We believe that this deal provides substantial value to shareholders, which was highlighted by the overwhelming support we received today. We look forward to delivering on this vote of confidence as we execute on our new strategy focused on opportunities in the U.S. market.”

To view the full press release, visit http://ibn.fm/64Gqs

About Canopy Rivers

Canopy Rivers is an investment and acquisition company specializing in cannabis with a portfolio of 17 companies across various segments of the cannabis value chain. The company believes that bringing together people, capital and ideas raises the potential of the entire cannabis industry. By leveraging its industry insights, in-house expertise and thesis-driven approach to investing, Canopy Rivers aims to provide shareholders with exposure to specialized and disruptive cannabis companies. As part of the arrangement, the company will also change its corporate name to RIV Capital Inc. Canopy Rivers  expects that further updates will be communicated under the new corporate name following the close of the arrangement. For more information about this company, please visit www.CanopyRivers.com.

NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://ibn.fm/CNPOF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$BRSF Signs Memorandum of Understanding with $EHVVF to Map Brain Response

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company with two FDA-cleared products, has entered into a memorandum of understanding (“MoU”) with Ehave, Inc. (OTC: EHVVF), a provider of digital therapeutics for the psychedelic and mental health sectors. The agreement calls for the two companies to work together to map brain response to psychedelics being administered as a treatment for chronic pain, depressions (both major and persistent), post-traumatic stress disorder, bipolar disorder, general anxiety, ADHD and schizophrenia. The two companies will also collaborate in the development of neural net algorithms for the mental-health sector. BRSF’s e-tattoo technology will be used to provide continuous monitoring in the studies. According to the announcement, the MoU calls for Ehave to integrate Brain Scientific’s NeuroCap and NeuroEEG to obtain data from patients in real time; Ehave may also use the two devices in clinical settings with Ehave’s partner healthcare providers in order to gather data about the electrophysiological changes in brain pre-, mid- and post-psychedelic drug administration. Initial plans indicate the collection research could start in Australia and then be implemented in other areas. The research and data will be jointly owned by both Ehave and Brain Scientific. “Our current EEG device is about the size of a stamp,” said Brain Scientific chairman Boris Goldstein in the press release. “By shrinking the technology, the system allows for continuous measurement during a person’s normal activities, while providing a non-intrusive way to monitor various disorders. We believe the future of EEG testing will be centered around the ability to gather more precise data through non-invasive measures of the brain via 3D temporary imprint or implanted graphene electrodes. By utilizing graphene, which has been called a ‘wonder material of the 21st century,’ Brain Scientific believes the size of the electrodes can be thinner than a human hair and will allow brain activity monitoring with minimal distraction from everyday life.”

To view the full press release, visit: https://ibn.fm/jwPjg

About Brain Scientific Inc.

Brain Scientific is a commercial-stage, health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. For more information about this company, please visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at http://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$AMST Finds Sweet Spot Amid Surging Demand for Online Learning

Amesite (NASDAQ: AMST) today announced its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. The publication, titled “Essential E-Learning Ecosystems Move to the Head of the Class,” discusses the trend toward digital online learning in education and business. Amesite is positioned as demand surges for customized and scalable online learning products in a single, easy-to-use format. The piece reads, “This is the sweet spot for Amesite Inc. (NASDAQ: AMST), an award-winning artificial intelligence (‘AI’) software company that delivers online learning ecosystems for business, higher education and K-12. Amesite’s product portfolio is complemented by a robust suite of services that help partners implement new programs and improve existing ones. Most recently, Amesite introduced Manage, a creative new functionality that enables schools and businesses to efficiently build and customize new courses, or onboard existing ones, at their own pace.”

To view the full press release, visit http://ibn.fm/qEoPm

About Amesite Inc.

Amesite is a high-tech artificial intelligence software company offering a cloud-based platform and content creation services for business, university and K-12 learning and upskilling. Amesite-offered courses and programs are branded to its customers. For more information, visit www.Amesite.com.

NOTE TO INVESTORS: The latest news and updates relating to AMST are available in the company’s newsroom at http://ibn.fm/AMST

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$XPHYF Announces Completion of European CE-IVD Application for 25-Minute COVID-19 RT-PCR Test

$WTER Reports Record Fiscal Third Quarter Revenue of $10.2 Million

The Alkaline Water Company Inc. (NASDAQ and CSE: WTER) (the “Company”) is a producer of bottled alkaline drinking water, flavor-infused waters, and CBD infused products sold under the brand name Alkaline88 ^® , A88™, and A88CBD™, respectively. Today, the Company announces that revenue increased $1.7 million year-over-year to $10.2 million for the fiscal third quarter ended December 31, 2020.

Key Highlights:

• Fiscal 2021 third-quarter record revenue of $10.2 million increased 20% year-over-year.
• Fiscal 2021 third-quarter earnings per share of ($0.06) improved by 14.3% compared to the prior-year quarter, of which ($0.01) was related to non-cash expenses.
• Direct Store Delivery (DSD) network now reaches over 10,000 customers.
• A88CBD™ line expands national distribution network with KeHE, UNFI, BettermentRS, and broker C.A. Fortune.

“We are proud to announce that we delivered record fiscal third quarter revenue of $10.2 million. Our E-Commerce, A88CBD, single-serve offerings, eco-friendly aluminum bottles, and flavor-infused waters all contributed toward the record. Each business line continues to grow, and we expect a significant contribution from them over the next 12 months,” stated Ricky Wright, President and CEO of The Alkaline Water Company. “We are excited that the momentum we gained over the summer in our flagship brand Alkaline88 continues. Based on 13 week Nielsen scanner data ending 12/26/20, we continue to be the fastest-growing top 10 value-added water in the country. We outperform the category volume growth by almost 2 times and the unit growth by over 5 times. We are now the 8 ^th largest vendor in the category. We see continued strength in the 1/23/21 Nielsen scanner data as well.”

“We believe that the strategic actions we have taken this year position us for strong growth and anticipate solid returns from the investments we are making in the coming fiscal year. Since the end of the quarter, we are working tirelessly on several initiatives. These include expanding our DSD strategy in strategic regions. The expansion plans should allow us to reach an additional 40,000 to 80,000 customers in the all-important convenience store channels. Based on the changing shopping habits of consumers, we have allocated additional resources to our E-Commerce and digital marketing strategies both in the water and CBD categories. We have tested and will expand on programs that have shown extraordinary ROI’s in our test markets. By expanding our outlays to these water and CBD initiatives, we expect to drive a significant amount of sales through both our E-Commerce sites in fiscal 2022. Our products will also be supported by our first-ever traditional marketing campaign led by the Davis Elen agency.”

“With the change in administration in Washington, we are hopeful that we will finally get clear guidance nationwide for our A88CBD products. In anticipation of this, we expanded our retail distribution network for our A88CBD products through KeHE, UNFI, BettermentRS, and C.A. Fortune. We continue to leverage our existing relationships to penetrate the brick-and-mortar retailers with our A88CBD products and expect to be in thousands of stores in the coming months.”

“On the operational side, we are in the process of expanding our domestic capacity for our raw materials and increased finished goods. We will be announcing new plants and new raw material providers that should increase our overall capacity and positively impact our gross margins. These initiatives will support all aspects of the anticipated growth in E-Commerce, A88CBD, Alkaline88 single-serve offerings, Alkaline88 eco-friendly aluminum bottles, and Alkaline88 flavor-infused waters.”

“In addition to increasing our gross margins and capacity, they will significantly decrease our carbon footprint as our new vendors will be closer to our existing plants. Since inception, we have focused on having the smallest carbon footprint per liter of any major water brand. In the past 52 weeks, we have taken major steps in reducing our carbon footprint. We have already begun to include 25% recycled PET in our bulk sizes. We continue to focus on sustainability throughout our new initiatives, as demonstrated by being the first national water company with an aluminum bottle. We are a Clean Beverage™ company and care about not only what goes into our products but what we can do to minimize our impact on the environment.”

“These and other initiatives, including international expansion and the rebounding hospitality industry, should contribute to significant revenue growth in fiscal 2022. Our Company and its operations are well-positioned to be an omnichannel lifestyle brand in fiscal 2022.”

Fiscal 2021 Third Quarter Financial Results (unaudited)

(All amounts are in U.S. dollars)

• For the fiscal third-quarter ending December 31, 2020, recorded record revenue of approximately $10.2 million, an increase of approximately 20% year-over-year.
• Gross profit in the fiscal third quarter of $4.2 million increased by 23.6% compared to the prior-year quarter.
  • Gross margin of 41.2% improved by 110 basis points primarily due to the increase in sales.
• Total operating expenses for the fiscal third quarter were $8.4 million, an increase of 37.0% year over year.
• Net loss for the fiscal third quarter was $4.4 million or $0.06 per share versus a net loss of $2.9 million or $0.07 per share in the fiscal third quarter of 2020. The bottom-line was impacted by ($0.01) per share due to certain non-cash items.s

Recent Business and Operational Highlights

National Footprint and Channel Expansion

• Alkaline88 ^® flagship brand of premium alkaline water is now available in over 75,000 stores across all trades in the U.S.
• Launched Direct Store Delivery (DSD) strategy with Mahaska.
• Alkaline88® 3-liters and A88-Infused flavors available in 99 Cent Only Stores across California, Texas, and Nevada.
• Sprouts to carry Alkaline88® eco-friendly aluminum bottles across all stores nationwide.
• Added C.A. E-Comm to support e-commerce growth.
• Expands into multi-billion dollar Hospitality and Foodservice channel.
  • Added Dot Foods Inc., the largest food redistributor in the U.S., to present our Alkaline88®, A88 Infused™, and eco-friendly aluminum bottles to its 4,300 customers nationwide.
  • Added Independent Broker Alliance (IBA), an alliance of 30 independently owned and operated foodservice sales agencies.
• Expanded national distribution with KeHE for flavor-infused waters and A88CBD™ topical products and BettermentRS, UNFI, and broker C.A. Fortune for its A88CBD™ portfolio of products.
• Adds Valu Merchandisers Company (VMC), a natural and organic product distributor serving more than 3,800 independently owned supermarkets in 35 states.
• HomeGoods, a T.J. Maxx company, to carry the new 2-liter product in 500 store locations.
• Alkaline88® available in 1-gallon and 1-liter sizes at all 123 Fareway store locations across 6 states in the Midwest.
• H-E-B to carry Alkaline88® aluminum bottles in 288 U.S. stores.
• Expands online and brick-and-mortar channels for A88CBD™ portfolio of products.
  • Products are now available in approximately 300 retail locations, including Elevated Wellness CBD, CBD Emporium, Alchemist Kitchen, Pure CBD, Vitamin Plus (select locations), and online at Amazon , CBD.co , healwithnature.com , and DirectCBDOnline.com .
• Accelerated convenience store growth strategy with several new distribution agreements.
  • Since the inception of the program, the Company has added over 12,000 new convenience stores and a target goal to reach approximately 25,000 convenience stores.

Innovation and Product Portfolio Expansion

• Launched new 2-liter single-serve and six-packs, targeting high volume shoppers, including the club market.
• Expanded topical product lineup; includes bath bombs and deep-relief cream made with high-quality, lab-tested hemp extract.
• Expanded ingestible product lineup; includes lemon-lime water, gummies, and powder packs made with high-quality, lab-tested hemp extract.
• Announced new single-serve 500ml eco-friendly aluminum bottles.

Corporate Development

• Appoints Retail Industry Veteran Frank Lazaran to its Board of Directors.
• Enhanced digital customer experience by adding new content and features to A88CBD.com
• Featured and showcased the A88 family of products at various national expos and tradeshows.
  • Ranked #1 best selling national brand by units sold at the 2020 KeHE Holidays of Hope show and the KeHE Winter Virtual show.

Brand Awareness

• Alkaline88 ^® remains the #1 selling bulk alkaline water nationally.

The following table summarizes the operating results for the three months ended December 30, 2020, and 2019 (Unaudited):

Conference Call Information

The Alkaline Water Company will conduct a conference call to review its operating results for the quarter ended December 31, 2020, on Tuesday, February 16, 2021, at 5:00 PM Eastern Time. This call may include material information not contained in this press release.

Date: February 16, 2021

Time: 5:00 PM Eastern Time (E.T.)

Dial-in Number for U.S. and Canadian Callers: 877-407-8293

Dial-in Number for International Callers (Outside of the U.S. and Canada): 201-389-0927

Participating in the call will be the Company’s President and CEO, Richard A. Wright, and Chief Financial Officer, David Guarino. They will discuss operational and financial highlights for the fiscal third quarter.

Please dial into the above-referenced telephone numbers five to 10 minutes prior to the scheduled call time to join the live conference call.

A replay will be available for one week starting on February 17, 2020, at approximately 10:30 AM (E.T.). To access the replay, please dial 877-660-6853 in the U.S. or Canada and 201-612-7415 for international callers. The conference I.D. # is 13716457.

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company (NASDAQ and CSE: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts our trademarked label ‘Clean Beverage.’ Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the Company launched A88 Infused Beverage Division Inc., which includes the Company’s CBD water and flavor-infused water. For the Company’s topical and ingestible offerings, A88 Infused Products Inc. includes both the Company’s lab-tested hemp extract salves, balms, lotions, essential oils, and bath salts, along with broad-spectrum hemp, powder packs, oil tinctures, capsules, and gummies.

To purchase A88CBD™ products online, visit us at A88CBD.com and Alkaline88.com . To learn more about The Alkaline Water Company, please visit www.thealkalinewaterco.com or connect with us on Facebook, Twitter, Instagram, or LinkedIn.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements.” Statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the following: that the Company expects a significant contribution from each business line over the next 12 months; that the Company believes that the strategic actions the Company has taken this year position the Company for strong growth and anticipate solid returns from the investments the Company is making in the coming fiscal year; that the expansion plans should allow the Company to reach an additional 40,000 to 80,000 customers in the all-important convenience store channels; that the Company will expand on programs that have shown extraordinary ROI’s in its test markets; that the Company expects to drive a significant amount of sales through both its E-Commerce sites in fiscal 2022; that the Company is hopeful that it will finally get clear guidance nationwide for its A88CBD products; that the Company expects that its A88CBD products to be in thousands of stores in the coming months; that new plants and new raw material providers that the Company will announce should increase the Company’s overall capacity and positively impact the Company’s gross margins and these initiatives will support all aspects of the anticipated growth in E-Commerce, A88CBD, Alkaline88 single-serve offerings, Alkaline88 eco-friendly aluminum bottles, and Alkaline88 flavor-infused waters and they will significantly decrease the Company’s carbon footprint as the Company’s new vendors will be closer to the Company’s existing plants; that these and other initiatives, including international expansion and the rebounding hospitality industry, should contribute to significant revenue growth in fiscal 2022; that the Company and its operations are well-positioned to be an omnichannel lifestyle brand in fiscal 2022 and the Company’s target goal to reach approximately 25,000 convenience stores.

The material assumptions supporting these forward-looking statements include, among others, that the demand for the Company’s products will continue to significantly grow; that the past production capacity of the Company’s co-packing facilities can be maintained or increased; that there will be increased production capacity through implementation of new production facilities, new co-packers and new technology; that there will be an increase in number of products available for sale to retailers and consumers; that there will be an expansion in geographical areas by national retailers carrying the Company’s products; that there will be an expansion into new national and regional grocery retailers; that there will be an expansion into new e-commerce, home delivery, convenience, and healthy food channels; that there will not be interruptions on production of the Company’s products; that there will not be a recall of products due to unintended contamination or other adverse events relating to the Company’s products; and that the Company will be able to obtain additional capital to meet the Company’s growing demand and satisfy the capital expenditure requirements needed to increase production and support sales activity. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, governmental regulations being implemented regarding the production and sale of alkaline water or any other products, including products containing hemp/CBD; the fact that consumers may not embrace and purchase any of the Company’s CBD-infused products; the fact that the Company may not be permitted by the FDA or other regulatory authority to market or sell any of its CBD-infused products; additional competitors selling alkaline water and enhanced water products in bulk containers reducing the Company’s sales; the fact that the Company does not own or operate any of its production facilities and that co-packers may not renew current agreements and/or not satisfy increased production quotas; the fact that the Company has a limited number of suppliers of its unique bulk bottles; the potential for supply-chain interruption due to factors beyond the Company’s control; the fact that there may be a recall of products due to unintended contamination; the inherent uncertainties associated with operating as an early stage company; changes in customer demand and the fact that consumers may not embrace enhanced water products as expected or at all; the extent to which the Company is successful in gaining new long-term relationships with new retailers and retaining existing relationships with retailers; the Company’s ability to raise the additional funding that it will need to continue to pursue its business, planned capital expansion and sales activity; and competition in the industry in which the Company operates and market conditions. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States and Canada. Although the Company believes that any beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Readers should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents the Company files with the SEC, available at www.sec.gov , and on the SEDAR, available at www.sedar.com .

View source version on businesswire.com: https://www.businesswire.com/news/home/20210216006047/en/

The Alkaline Water Company Inc.

Richard A. Wright
President and CEO

Sajid Daudi
Director of Investor Relations & Corporate Communications
800-923-1910
investors@thealkalinewaterco.com

Media

Jessica Starman
888-461-2233
jessica@elev8newmedia.com

$TOBAF Announces Availability of Flagship Product Through Online Website

TAAT(TM) Lifestyle & Wellness (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) has announced that, effective Wednesday, Feb. 18, at 9 a.m. ET, its ecommerce portal will be live and operational, with smokers in the United States aged 21 years of age and older being able to purchase the company’s flagship product — TAAT(TM) Original, Smooth and Menthol — by the carton in certain areas. The product is currently available for retail sale throughout the state of Ohio. In the announcement, the company noted that it believed that selling its product online would accelerate its entry into new markets across the country. The company will also watch online sales closely to gain valuable insights regarding potential new markets. “Selling TAAT online can create a number of advantages for us in the USD $814 billion tobacco industry,” said TAAT CEO Setti Coscarella in the press release. “Foremost, we will be able to benefit from an unprecedented market reach as soon as the online store launches, as opposed to having to set up distribution from scratch in each and every new market. Second, the online sales channel can provide us a much greater degree of insight into the tendencies and preferences of smokers aged 21+ who purchase TAAT directly from us. Additionally, by selling directly to our customer base, we expect we will be able to maintain some very favorable profit margins. . . . By combining our online sales with initiatives that are currently being led by CROSSMARK to place TAAT in convenience store points of sale across the country, I believe we are in a very good position to capture additional market share at a much faster rate.”

To view the online product website, visit http://trytaat.com

To view the full press release, visit http://ibn.fm/G1YQs

About TAAT(TM) Lifestyle & Wellness Ltd.

TAAT Lifestyle and Wellness has developed TAAT,  which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco(TM), a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, please visit www.TAATGlobal.com.

NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at http://ibn.fm/TOBAF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$SRAX Sequire Platform Provides Exclusive Access to B. Riley Vision Day Content; Company Announces Closing on BIGtoken Transaction

$POAI Announces Closing of $7.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

MINNEAPOLIS, Feb. 16, 2021 — Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously announced registered direct offering of 4,222,288 shares of its common stock, at a purchase price of $1.75 per share, which was priced at-the-market under Nasdaq rules. The gross proceeds to the Company from this offering were approximately $7.4 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. In a concurrent private placement, the Company also issued to the same investors unregistered warrants to purchase up to an aggregate of 2,111,144 shares of common stock at an exercise price of $2.00 per share. The warrants are exercisable immediately upon issuance and have a term and five and one-half years.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The Company intends to use the net proceeds from the offering for working capital purposes.

The shares of common stock described above (but not the warrants or the shares of common stock underlying the warrants) were offered by the Company in a registered direct offering pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-234073), including a base prospectus previously filed with the Securities and Exchange Commission (the “SEC”) on October 3, 2019, that became effective on December 19, 2019. A final prospectus supplement and base prospectus relating to the registered direct offering was filed with the SEC and is available on the SEC’s website located at http://www.sec.gov . Electronic copies of the prospectus supplement and the accompanying base prospectus may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646-975-6996 or e-mail at placements@hcwco.com .

The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and the underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information, please visit www.predictive-oncology.com .

Forward-looking Statements

Certain of the matters discussed in this press release contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include: market and other conditions and the intended use of net proceeds from the registered direct offering, a variety of other risks and uncertainties including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Landon Capital
Keith Pinder
(404) 995-6671
kpinder@landoncapital.net

$PLTXF Announces Public Offering of Units

VANCOUVER, BC , Feb. 16, 2021 – PlantX Life Inc. (the ” Company ” or ” PlantX “) (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF) is pleased to announce it has filed a preliminary short form prospectus in connection with a marketed public offering (the ” Offering “) of units of the Company (the ” Units “).

Each Unit will consist of one (1) common share of the Company (” Common Share “) and one (1) Common Share purchase warrant (a ” Warrant “). Each Warrant will entitle the holder to purchase one additional Common Share for a period of two (2) years from the closing of the Offering (the ” Closing “), provided that, if, at any time, the daily volume weighted average trading price (or closing price on trading days when there are no trades) of the Common Shares on the Canadian Securities Exchange (the ” CSE “) or, if the Common Shares are not listed on the CSE, then on such other recognized Canadian stock exchange on which the Common Shares are then listed, equals or exceeds a specified price per Common Share over any 10 consecutive trading days, the Company shall be entitled, at its option, within 10 business days following such 10-day period, to accelerate the exercise period of the Warrants through the issuance of a press release (the ” Acceleration Notice “) specifying the new expiry date and, in such case, the Warrants will expire on the 30th day following the issuance of the Acceleration Notice. From and after the new expiry date specified in such Acceleration Notice, no Warrants may be issued or exercised, and all unexercised Warrants shall be void and of no effect following the new expiry date (the ” Acceleration Provision “).

The size of the Offering, the pricing of each Unit, the exercise price of each Warrant and of the Compensation Options (as defined below), and the terms of the Acceleration Provision will be determined in the context of the market prior to the filing of an amended and restated short form prospectus in respect of the Offering.

Mackie Research Capital Corporation (the ” Agent “) will be acting as the lead agent and sole bookrunner for the Offering. At the Closing, the Company will pay to the Agent a cash commission of 6% of the aggregate gross proceeds arising from the Offering other than in connection with a president’s list of investors (the ” President’s List Investors “), in which case the cash commission shall be 4% of the proceeds raised from President’s List Investors. In addition, and subject to regulatory approval, the Agent will receive compensation options (the ” Compensation Options “) exercisable at any time up to 24 months following Closing to purchase Common Shares in an amount equal to 6% of the number of Units sold in connection with the Offering (other than in connection with President’s List Investors, in which case the number of Compensation Options shall be 4% of the number of Units sold to President’s List Investors).

The Company intends to use the net proceeds from the Offering to fund expansion, to continue to develop a user app, to evaluate and pursue potential strategic acquisitions, and for working capital and general corporate purposes.

The Closing is currently expected to be on or about March 11, 2021 or such other date as agreed upon between the Company and the Agent, and is subject to certain conditions including, but not limited to, the execution of an agency agreement and the receipt of all necessary regulatory approvals including the approval of the CSE.

The Units are to be sold on a “best efforts” basis through the Agent in the provinces of British Columbia , Alberta and Ontario , and such other jurisdictions as the Agent and the Company may agree other than Quebec , and in the United States pursuant to available exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the ” U.S. Securities Act “) and all applicable U.S. state securities laws.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities in the United States or to, or for the account or benefit of, U.S. persons. The securities described herein have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. “United States” and “U.S. person” are as defined in Regulation S under the U.S. Securities Act.

About PlantX Life Inc.

As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the Company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the Company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand – but the business is not limited to an e-commerce platform. The Company uses its digital platform to build a community of likeminded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The Company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life.

On behalf of the board of directors of PlantX

Julia Frank
Chief Executive Officer

The Company website is http://investor.PlantX.com/ .

Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may,” “will,” “expect,” “likely,” “should,” “would,” “plan,” “anticipate,” “intend,” “potential,” “proposed,” “estimate,” “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. The forward-looking information contained herein includes, without limitation, the business and strategic plans of the Company, expectations and assumptions regarding the terms, timing and potential completion of the Offering; satisfaction of regulatory requirements in various jurisdictions and the use of proceeds from the Offering.

By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate; that assumptions may not be correct; and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release including, without limitation: the Company’s ability to comply with all applicable governmental regulations, including all applicable food safety laws and regulations; impacts to the business and operations of the Company due to the COVID-19 epidemic; a limited operating history; the ability of the Company to access capital to meet future financing needs; the Company’s reliance on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.

Additional risk factors can also be found in the Company’s continuous disclosure documents, which have been filed on SEDAR and can be accessed at www.sedar.com . Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

$MGROF Plant-Based Biopesticide Achieves 100% Control of Root-Rot Disease in Recent Studies

$KAVL Announces Packaging Revisions Project Completion, Positive Q1 2021 Expectations

Kaival Brands (OTCQB: KAVL), a company focused on generating shareholder value by incubating innovative products into mature and dominant brands within their respective markets, has noted that a Q4 project involving a redesign of Bidi(R) Vapor LLC’s packaging and labeling for its entire product line has been completed. The redesign decision was made as the Bidi company opted to meet and exceed the FDA’s proposed guidelines for all of its product, which meant the company halted production of its products until the project was finished. Kaival is the exclusive global distributor of all products manufactured by Bidi Vapor, including the Bidi(R)Stick, which is the fastest-growing closed system vaping product in the United States. KAVL also recently launched the Bidi(R)Pouch, a tobacco-free nicotine pouch available in six flavors. During Q4, Kaival was limited in the volume of products available because of the redesign project, which included changing the names of the product suite to nondescriptive, one-word monikers and bolstering safety and hazard warnings on product packaging. The announcement noted that, as a result of the redesign project, KAVL experienced significant loss in revenue opportunity during Q4 2020; however, with the project completed, the company has successfully restarted its sales and marketing process with revenues tracking close to $40 million. “It should be understood, that under no circumstance will Kaival Brands distribute, market, promote, or sell any product that would have deleterious consequences to the community and APPI guidelines,” said Kaival Brands CEO Niraj Patel in the press release. “We have created a premium experience assisting current adult cigarette smokers age 21 and older to choose alternative options to traditional, combustible cigarettes. Kaival Brands will never behave in a manner that compromises health or the environment.”

To view the full press release, visit http://ibn.fm/BEiiP

About Kaival Brands Innovations Group Inc.

Kaival Brands is focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. Kaival’s vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. For more information, visit the company’s website at www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$HWAL Selects IBN as Official Corporate Communications Partner

Hollywall Entertainment (OTC: HWAL), a telecommunications, media, technology, broadcasting and entertainment company, announced that it has chosen InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, to provide its corporate communications. The announcement noted that as part of the partnership, IBN will distribute Hollywall news and communications throughout its comprehensive distribution network of 5,000-plus syndication outlets; IBN will also leverage is wide range of newsletters, social media channels, blogs, and wire services to build and strengthen awareness for Hollywall. Hollywall’s portfolio spans a wide range of industries, including infrastructure development, 5G and telecommunications, broadcasting, education, media and entertainment. Through its development company, Hollywall builds, restores and creates “smart” communities and fiber networks across the country. “We are pleased to engage IBN to maximize our communication with existing and potential shareholders as we continue to refine our overall messaging and outreach,” said Hollywall founder, chairman and CEO Darnell Sutton in the press release. “Hollywall remains fully committed to our time-honored promise of bringing forth great shareholder value and revenue, while offering state-of-the-art products and services designed to close an ever-widening digital divide that continues to permeate and erode the fragile growth of our nation’s most precious underserved and disadvantaged communities. Our offerings have only become further enhanced by this exciting new alliance with IBN and its exceptional ability to share our storied, trademarked mission of ‘Fiber to the People’ with its vast network of investors, consumers and media outlets.”

To view the full press release, visit https://ibn.fm/oEL78

About Hollywall Entertainment Inc.

Hollywall Entertainment is a telecommunications, technology, media, entertainment and broadcasting company that operates through its various subsidiaries, including Hollywall Development Company, HW Vision and HW Latlong, and multiple divisions to include HW School of Communications, Hollywall Music, Hollywall TV, HW Productions, HW Networks, HWRadio, HWGOV and The Hollywall Foundation. HWAL continues to maximize rights to its music, film, television, home videos and software game libraries. Hollywall owns exclusive and nonexclusive rights to market, manufacture and distribute music master recordings performed by legends such as Ray Charles, Ella Fitzgerald, the Jackson 5, Frank Sinatra, Dolly Parton, Elvis Presley, Tony Bennett, the Bee Gees, Chicago, the Platters, George Gershwin, Marvin Gaye, James Brown, the Who, Janis Joplin, Rolling Stones, Nat King Cole, John Lee Hooker, Willie Nelson, Rod Stewart, Hall and Oates, James Taylor, Etta James, Aretha Franklin and other multiple-platinum-selling acts. For more information, visit the company’s website at www.Hollywall.com.

NOTE TO INVESTORS: The latest news and updates relating to HWAL are available in the company’s newsroom at http://ibn.fm/HWAL

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$CLXPF Psilocybin Extracts Could Be the Key to Unlocking Psychedelic Health and Wellness

FN Media Group Presents Microsmallcap.com Market Commentary

New York, NY – February 16, 2021 – Psychedelics have made some spectacular breakthroughs to gain legitimacy as mental healthcare products and to become an emerging health and wellness market of its own. As these products enter the regulated consumer market, however, it’s important that they are reliably and accurately dosed to ensure user health and safety. Accurate dosing is difficult to achieve with botanicals, which is why forward-thinking psychedelics companies are developing new extracted products designed for the most accurate dosing possible. These innovative products include oral tablets, capsules, nasal gels, and more. Forward thinking companies like Pure Extracts (CSE: PULL) (OTCPK: PRXTF), Compass Pathways (NASDAQ: CMPS), Cybin Inc (NEO: CYBN) (OTCPK: CLXPF), AIkido Pharma Inc (NASDAQ: AIKI), and Numinus Wellness (TSXV: NUMI) (OTCPK: LKYSF) are advancing psychedelic medicine with research and development into the best ways to administer these revolutionary treatments.

Pure Extracts Developing State-of-the-Art Psychedelics Extracts

Pure Extracts (CSE:PULL) (OTC:PRXTF) is a Canadian company specializing in functional mushrooms and psychedelics with extensive extraction and production experience. The Company utilizes cutting-edge, sub and super-critical CO _² and ethanol extraction technology to produce high-quality, high purity formulations on a commercial scale. As psychedelic health and wellness continues its development, Pure Extracts is set up to deliver solvent-free, white-label formulations to service contract sales.

Pure Extracts conducts its extraction at its state-of-the-art facility in Pemberton, British Columbia, located 30 kms north of famed Whistler Resort. The facility is built to EU-GMP specifications, allowing for certification so that the Company will be able to sell its products internationally. On December 16, Pure Extracts announced that the Company had begun to build-out the fourth unit in its facility. This unit is specifically designed for extraction of mushrooms and for research and development of psilocybin. Pure Extracts is currently preparing its application for a Health Canada Dealer’s Licence under the Controlled Drugs and Substances Act, which will allow the company to produce, distribute, and sell psilocybin products.

On December 30, Pure Extracts announced the commencement of a new study on the formulation and manufacturing of psilocybin-based active treatments for oral tablets, capsules, and a nasal gel. Conducted at the Toronto Institute of Pharmaceutical Technology by Dr. Alexander MacGregor, the study will focus on formulating, manufacturing, and clinical bioavailability testing of rapid onset psilocybin dosage forms that could be used in future efficacy clinical trials by both Pure Extracts and its pharmaceutical customers.

“We are excited about the R&D progress we are going to make with TIPT over the next six to eight months while waiting to receive our Dealer’s License from Health Canada,” Pure Extracts CEO Ben Nikolaevsky said in the Company’s release. “We will be well prepared for our move into the controlled substances world of psychedelics and will have advanced knowledge regarding psilocybin and its associated novel delivery mechanisms.”

Biotech Space Develops Extracted Psychedelic Therapeutics

Compass Pathways (NASDAQ:CMPS) sent shockwaves through the psychedelics space last year when it became the first psychedelics company to list on a major US exchange with its listing on the NASDAQ. The company has continued its research and development into psychedelics, announcing on February 9 the expansion of its Discovery Center and research collaborations with three of the world’s most eminent scientists in psychedelic research.

In the fight towards therapeutic breakthroughs for mental health disorders, Cybin Inc (NEO:CYBN) (OTC:CLXPF) has entered into a partnership with Kernel to utilize its Kernel Flow technology to quantify brain activity during psychedelic experiences. Cybin believes that this clinical work could help to fill in the gaps for targeting neurological disorders.

Diversified biotechnology company AIkido Pharma Inc (NASDAQ:AIKI) announced in January that the company had executed a patent license agreement for technology related to psilocybin for cancer treatment and treatment of cancer side-effects. AIkido has been focused on small-molecule anti-cancer therapeutics for decades and the company’s CEO says that they believe psychedelics to be an expanding area of treatment.

On February 8, psychedelic-focused mental health and wellness company Numinus Wellness (TSXV:NUMI) (OTCPK:LKYSF) completed its acquisition of Montreal-based full-service well-being organization Mindspace Psychology Services Inc. The company describes Mindspace as “a leader and pioneer in psychedelic programming.”

Psychedelics could be the future of health and wellness, and extracted products like those developed by Pure Extracts could be key to unlocking the safe and reliable therapeutic benefits of these products.

To learn more about Pure Extracts , please click here.

DISCLAIMER: Microsmallcap.com (MSC) is the source of the Article and content set forth above.  References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Pure Extracts.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.

Media Contact:
FN Media Group, LLC
info@financialnews.com
+1(561)325-8757

$CNPOF Shareholders Approve Plan of Arrangement with Canopy Growth

TORONTO , Feb. 16, 2021  – Canopy Rivers Inc. (” Rivers ” or the ” Company “) (TSX: RIV) (OTC: CNPOF) is pleased to announce that its shareholders voted today to approve the previously announced plan of arrangement (the ” Arrangement “) involving Canopy Growth Corporation (” Canopy Growth “) (TSX: WEED) (NASDAQ: CGC).

Approximately 99.87% of the votes cast by Rivers’ shareholders were voted in favour of the Arrangement, including approximately 99.85% of the votes cast by Rivers’ shareholders other than Canopy Growth, whose votes were required to be excluded pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions . Approval was required from at least (i) two-thirds of the votes cast by the holders of Subordinated Voting Shares (” SVS “), voting separately as a class; (ii) two-thirds of the votes cast by Canopy Growth, as the sole holder of all of the Multiple Voting Shares (” MVS “), voting separately as a class; and (iii) a simple majority of votes cast by holders of SVS, voting separately as a class, excluding the votes attaching to the SVS held by Canopy Growth.

“We are thrilled by both the high voting turnout and the tremendous support we received for the Arrangement,” said Narbe Alexandrian, President and CEO, Rivers. “We believe that this deal provides substantial value to shareholders, which was highlighted by the overwhelming support we received today. We look forward to delivering on this vote of confidence as we execute on our new strategy focused on opportunities in the U.S. market.”

Right of First Refusal in respect of the Vert Mirabel Shares

The Company also announced today that Les Serres Stéphane Bertrand Inc. (” Serres Bertrand “) has exercised its right of first refusal to purchase its proportionate interest of the common shares (the ” ROFR Shares “) in Les Serres Vert Cannabis Inc. (” Vert Mirabel “) from Rivers, which was triggered as a result of the Arrangement.

Accordingly, the Company, through its wholly-owned subsidiary, RIV Capital Corporation (formerly Canopy Rivers Corporation) (” RCC “), has entered into a definitive purchase agreement (the ” Share Purchase Agreement “) with Serres Bertrand in respect of the ROFR Shares, pursuant to which RCC will sell to Serres Bertrand 117 ROFR Shares, representing 11.7% of the issued and outstanding common shares of Vert Mirabel, for cash consideration of approximately $3.4 million (the ” ROFR Transaction “).

The ROFR Transaction is expected to be completed on the same day as the Arrangement, subject to the satisfaction of certain conditions in favour of RCC, including the deposit by Serres Bertrand of the cash consideration, and the consummation of the Arrangement. The Company expects that both the Arrangement and the ROFR Transaction will close prior to the end of February.

The ROFR Transaction will result in a downward adjustment to the number of common shares of Canopy Growth that RCC will receive pursuant to the Arrangement by approximately 103,000 shares, such that RCC will now receive approximately 3.65 million common shares of Canopy Growth. The remaining shares of Vert Mirabel held by RCC will be transferred to Canopy Growth pursuant to the Arrangement. If the conditions to completion of the ROFR Transaction are not satisfied, all of the ROFR Shares will be transferred to Canopy Growth as part of the Arrangement.

About Canopy Rivers Inc.

Canopy Rivers is an investment and acquisition company specializing in cannabis with a portfolio of 17 companies across various segments of the cannabis value chain. We believe that bringing together people, capital, and ideas raises the potential of the entire cannabis industry. By leveraging our industry insights, in-house expertise, and thesis-driven approach to investing, we aim to provide shareholders with exposure to specialized and disruptive cannabis companies.

As part of the Arrangement, the Company will also change its corporate name to “RIV Capital Inc.” The Company expects that further updates will be communicated under the new corporate name following the close of the Arrangement.

Forward-Looking Statements

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. To the extent any forward-looking information in this news release constitutes “financial outlooks” within the meaning of applicable Canadian securities laws, the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: the Company’s belief that the ROFR Transaction will be completed; the anticipated cash proceeds from the ROFR Transaction; Serres Bertrand’s ability to meet certain conditions in order to complete the ROFR Transaction; the Company’s belief that the Arrangement and the ROFR Transaction will close on the same day; the value provided to shareholders by the Arrangement; that shareholders supported the Arrangement because of the values derived from it; the Company’s anticipated focus on its strategy in the U.S. market; the Company’s expectation that the Arrangement will close prior to the end of February 2021 ; and the Company’s expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein. Our actual financial position and results of operations may differ materially from management’s current expectations.

Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the possibility that the Arrangement will not be completed on the terms and conditions, or on the timing, currently contemplated, and that it may not be completed at all, due to a failure to obtain or satisfy, in a timely manner or otherwise, the required approval of the court, or other approvals and other conditions of closing necessary to complete the Arrangement, or for other reasons, the occurrence of any event, change or other circumstances that could give rise to the termination of the Arrangement; the possibility that the ROFR Transaction will not be completed on the terms and conditions, or on the timing, currently contemplated, and that it may not be completed at all, due to a failure to obtain or satisfy, in a timely manner or otherwise, the conditions of closing necessary to complete the ROFR Transaction, or for other reasons, the occurrence of any event, change or other circumstances that could give rise to the termination of the Share Purchase Agreement; the delay of implementation of the Arrangement or failure to complete the Arrangement for any reason; the Company’s ability to alter its capital structure on the anticipated terms; the inability of Serres Bertrand to meet certain conditions pursuant to the Share Purchase Agreement, including the delivery of the cash consideration thereunder; credit liquidity, and additional financing risks for the Company and its investees; the entry into the U.S. market by the Company; the potential for the company’s board of directors and shareholders to be prosecuted for aiding and abetting violations of U.S. federal law; enhanced scrutiny of the Company’s investments and operations if the Company invests in or operates U.S. cannabis businesses; the effect of operating or investing in the U.S. on the Company’s existing contractual arrangements and business relationships; the risks associated with U.S. banking and anti-money laundering laws and regulations; the classification of the Company’s income as proceeds of crime and the ability of the Company to declare or pay dividends or effect other distributions or the repatriation of funds back to Canada ; risks associated with the termination, renegotiation and enforcement of material contracts; credit, liquidity and additional financing risks for the Company and its investees; litigation risks; stock market volatility; regulatory and licensing risks; cannabis pricing risks; changes in cannabis industry growth and trends; changes in the business activities, focus and plans of the Company and its investees and the timing associated therewith; the Company’s actual financial results and ability to manage its cash resources; changes in general economic, business and political conditions, including challenging global financial conditions and the impact of the novel coronavirus pandemic; competition risks; potential conflicts of interest; the regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; changes in the Company’s relationship with Canopy Growth and its investees; changes in applicable laws; compliance with extensive government regulation, including the Company’s interpretation of such regulation; changes in the global sentiment towards, and public opinion of, the cannabis industry; reliance on material contracts; risk of default by investees; divestiture risks; and the risk factors set out in the Company’s annual information form for the year ended March 31, 2020 and the Company’s management information circular in connection with the Arrangement, filed with the Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com .

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

$AZRX Announces Participation in Microcap Rodeo Winter Wonderland Conference

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, has announced that it will present at the upcoming Microcap Rodeo Winter Wonderland Conference. The virtual conference is slated for Feb. 16–19, 2021. AzurRx CEO James Sapirstein is scheduled to make a live company presentation during the conference. The AzurRx presentation is scheduled for 4:30 p.m. ET on Feb. 17. During the presentation, Sapirstein will provide an overview of AzurRx’s business and clinical development programs; he will also talk about milestones anticipated throughout the coming year. Following the presentation, Sapirstein and other AzurRx executives will be available to meet one-on-one with registered investors.

To register for the event, visit https://ibn.fm/AtvyK

To view the full press release, visit http://ibn.fm/TiWOg

About AzurRx BioPharma Inc.

AzurRx BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The first is MS1819, a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, with two ongoing phase 2 clinical trials. The other two are clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor: FW-420, for the treatment of grade 1 immune checkpoint inhibitor associated colitis (“ICI-AC”) and diarrhea in oncology patients, and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$AMST Essential E-Learning Ecosystems Move to the Head of the Class

$XPHYF Development on Nasal Spray That Protects Against Common Cold, Coronavirus

$VTGN Releases Q3 Financial Report, Clinical Studies Update

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has reported its financial numbers for its fiscal 2021 third quarter, ending Dec. 21, 2020. Highlights of the report are the company’s strengthened balance sheet following the closing of its recent underwritten public offering, which resulted in $100 million. In the report, the company also noted that it expects to launch multiple clinical studies during the 2021 calendar year, including crucial Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder (“SAD”). Other planned exploratory trials include PH94B Phase 2 studies in adult patients experiencing additional anxiety-related disorder; the company is also planning on completing preparation for the Phase 2B clinical development of its PH10 as a potential rapid-onset standalone treatment for major depressive disorder in early 2022. “Calendar 2020 was transformative, highlighted by closing a PH94B partnership, a positive meeting with the FDA regarding the key aspects of the study design for our upcoming pivotal Phase 3 studies of our PH94B nasal spray in social anxiety disorder and, during the most recent quarter, closing a $100 million financing which involved significant participation from leading healthcare institutional investors such as Acuta Capital, New Enterprise Associates, OrbiMed and Venrock Healthcare Capital Partners, among others,” said VistaGen CEO Shawn Singh in the press release. “We are encouraged by these transformative milestones. Together, they have further advanced our tenacious pursuit to bring life-changing medications to the millions affected by anxiety, depression and other mental health challenges worldwide.”

To view the full press release, visit: https://ibn.fm/5C7Pu

About VistaGen Therapeutics Inc.

VistaGen is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information about the company, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$TOBAF Featured in Seeking Alpha Article

TAAT(TM) (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) today announced that it has received new media coverage with a well-known finance publication, after a feature in Forbes on Feb. 3, 2021. According to the update, a Feb. 11 blog article published on Seeking Alpha discusses recent patterns in the consumer packaged goods (“CPG”) industry, in which analogues to popular product types ( e.g. , meat, alcohol) have gained market share seemingly due to the element of choice they provide to consumers. The article notes that the company’s flagship product TAAT(TM) appears to fit into this pattern as an alternative to tobacco cigarettes. “It is an honour for TAAT(TM) to keep getting media attention as we introduce our product line to smokers aged 21+ in the United States to offer them a better choice. Since December 2020, we have been placing TAAT(TM) in tobacco retailers across the state of Ohio, with several stores having sold out and reordered in just a matter of weeks,” said TAAT(TM) Chief Executive Officer Setti Coscarella. “Although TAAT(TM) has already been mentioned in various regional and niche publications, coverage in outlets that reach a much wider audience is very validating both of the TAAT(TM) product itself, as well as the company as a whole. I believe the Seeking Alpha author did an excellent job of painting a macro-level picture of the CPG and tobacco industries in today’s article, also explaining where TAAT(TM) could fit in among other products that have taken a novel approach to capturing market share through reinvented formulations that provide what consumers ultimately want most, and that is choice.”

To view the full press release, visit http://ibn.fm/NIKGZ

About TAAT(TM) Lifestyle & Wellness Ltd.

The company has developed TAAT(TM), which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in “Original,” “Smooth” and “Menthol” varieties. TAAT(TM)’s base material is Beyond Tobacco(TM), a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with “Big Tobacco” pedigree, TAAT(TM) was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion* global tobacco industry. For more information, please visit www.TAATGlobal.com.

*British American Tobacco – The Global Market

NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at http://ibn.fm/TOBAF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

$PBIO Announces Plans to Acquire the Assets of Global Eco-Friendly Agrochemical Supplier

$MGROF Qualifies to Trade on OTCQX Best Market

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, has announced it has qualified to trade on the OTCQX(R) Best Market; the company’s symbol was also upgraded to OTCQX from the OTCQB(R) Venture Market. Effective Friday, Feb. 12, 2021, the company will begin trading using its MGROF symbol. The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Moving from the OTCQB market to the OTCQX Market allows companies an opportunity to build visibility among investors in the United States. “It has been a great experience to be traded on the OTCQB Venture Market and the service we have received has been second to none,” said MustGrow president and CEO Corey Giasson in the press release. “We are excited that OTC Markets Group invited us to graduate to its highest market tier and look forward to what the future holds for MustGrow on the OTCQX Best Market.”

To view the full press release, visit: https://ibn.fm/63gjK

About MustGrow Biologics Corp.

MustGrow is a publicly traded, agriculture biotech company focused on providing natural, science-based biological solutions for high-value crops, including fruits and vegetables. MustGrow has designed and owns a U.S. EPA-approved natural solution that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s Pest Management Regulatory Agency (“PMRA”) as a biopesticide for high-value crops, including fruits and vegetables. MustGrow has now concentrated a liquid format, TerraMG, that with regulatory approval could be applied through standard drip or spray equipment, improving functionality and performance features. In addition, this mustard-derived technology could have other applications in several different industries from pre-plant soil treatment to post harvest disease control and food preservation. For more information about the company, please visit www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at http://ibn.fm/MGROF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

$LXXGF Announces Change in Management, New Board Appointment

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that Daryl Rebeck will resign from the board and his position as the president of LexaGene effective Feb. 15, 2021. Stephen J. Mastrocola has joined the company’s board of directors and brings almost 40 years of accounting and auditing experience working with public and private companies. “I’m immensely grateful to Daryl for being my partner and helping me found this company four years ago. I would like to thank him for all his hard work and leadership and wish him great success in his future endeavors,” said Dr. Jack Regan, LexaGene’s CEO and founder. “We are extremely excited to have Steve join our board. He brings strong leadership skills, a wealth of knowledge, and connections in the industry that will be critical for LexaGene to meet its growth goals in 2021 and beyond.”

To view the full press release, visit: https://ibn.fm/0O9cI

About LexaGene Holdings Inc.

LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press “go.” The MiQLab(TM) system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information, visit the company’s website at www.LexaGene.com.

NOTE TO INVESTORS: The latest news and updates relating to LXXGF are available in the company’s newsroom at http://ibn.fm/LXXGF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.